Cite
APA Citation
Overman, M., Javle, M., Davis, R. E., Vats, P., Kumar-Sinha, C., Xiao, L., Mettu, N. B., Parra, E. R., Benson, A. B., Lopez, C. D., Munugalavadla, V., Patel, P., Tao, L., Neelapu, S., & Maitra, A. (2020). randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Journal for immunotherapy of cancer, 8(1), . http://access.bl.uk/ark:/81055/vdc_100127575173.0x00003a